



**THE FOUNDATION
FOR SECURE
MARKETS®**

#52000

Date: February 23, 2023

Subject: Imara Inc. - Reverse Split and Name/Symbol/CUSIP Change
Option Symbol: IMRA
New Symbol: ELVN1
Date: 02/24/2023

Imara Inc. (IMRA) has announced a 1-for-4 reverse stock split, and a name, symbol, and CUSIP change, in conjunction with a business combination with Enliven Therapeutics, Inc. As a result, each IMRA Common Share will be converted into the right to receive 0.25 (New) Enliven Therapeutics, Inc. (ELVN) Common Shares. The reverse stock split and underlying changes will become effective before the market open on February 24, 2023.

Additionally, under a CVR agreement, IMRA shareholders of record immediately prior to the effective time of the merger will receive one non-transferable Contingent Value Right (CVR) per share. The CVR represents a non-transferable contractual right to receive payments upon the occurrence of certain events related to the Asset Sale, as described in the Proxy Statement/Prospectus dated January 23, 2023.

IMRA options will not be adjusted to call for the delivery of the CVRs.

Contract Adjustment

Effective Date: February 24, 2023

Option Symbol: IMRA changes to ELVN1

Contract Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable Per Contract: 25 (New) Enliven Therapeutics, Inc. (ELVN) Common Shares

CUSIP: ELVN (New): 29337E102

Pricing

The underlying price for ELVN1 will be determined as follows:

ELVN1 = 0.25 (ELVN)

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.